Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Our study reveals that the PD-1 receptor functions optimally as dimers driven by interactions within the transmembrane domain on the surface of T cells, contrary to the dogma that PD-1 is a monomer." ...

In patients with PD-L1 expression of more than 5%, OS improved further to 16.4 months versus 12.8 months. Tevimbra targets the PD-1 receptor, a checkpoint protein that suppresses the immune response.

Background: The interaction of the PD-1 receptor on tumor infiltrating lymphocytes and PD-L1 on tumor cells dampens antitumor immunity. Two phase I trials suggested efficacy of anti-PD-1/PD-L1 ...

The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

A genetically diverse mouse model allowed researchers to identify genes that promote the success of immune checkpoint ...

They found that MCC-PD-1 receptor binding to its ligands accelerated tumor growth by activating the mammalian target of rapamycin (mTOR) ...

“Our study reveals that the PD-1 receptor functions optimally as dimers driven by interactions within the transmembrane domain on the surface of T cells, contrary to the dogma that PD-1 is a ...

Anti–CTLA-4 (ipilimumab) has not been tested as a single agent for patients with NSCLC, but has some activity in combination with chemotherapy. 2,3 In combination with anti–PD-1/PD-L1, the ...